CMPX

CTX-10726, a PD-1 x VEGF-A bispecific antibody discovered and engineered at Compass, exhibits a unique mechanism of action that has not been previously reported in this class of drugs, characterized by VEGF-A-dependent cleavage of PD-1 receptors from T cells resulting in conversion of PD-1 positive T cells into PD-1 negative T cells.  PD-1 receptor cleavage by CTX-10726 was only observed in the presence of VEGF-A, suggesting targeted activity in the tumor microenvironment.

BOSTON, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that the Company will participate in the following investor events during the month of November/this quarter. Details are as follows: Guggenheim 3rd Annual Healthcare Innovation Conference Date: Monday, November 9, 2026 Time: 1:30 PM ETWebcast Link: https://event.summitcast.com/view/ Stifel 2026 Healthcare Conference Date: Wednesday, November 11, 2026Time: 11:20 AM ETWebcast Link: https://event.summitcast.com/view/ Virtual/Replay availability: Presentations will be archived on Compass'  Events  page.

BOSTON, Oct. 14, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced it granted stock options to a new employee under the Company's 2025 Inducement Plan and as a material inducement to their employment in accordance with Nasdaq Listing Rule 5635(c)(4).

Compass Therapeutics faces a major setback after tovecimig failed to show an overall survival benefit in biliary tract cancer. CMPX plans to pursue a BLA submission for tovecimig despite FDA guidance recommending a new survival-focused trial. Financial runway extends into 2028, but delays or regulatory setbacks could force CMPX to raise capital from a weakened position.

BOSTON, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that the U.S. Food and Drug Administration (FDA) recommended that Compass conduct a trial demonstrating a survival benefit before proceeding with a Biologics License Application (BLA) submission for tovecimig in patients with previously treated, advanced biliary tract cancer (BTC).

The Company expects feedback from the FDA this quarter regarding the COMPANION-002 Phase 2/3 data for tovecimig (DLL4 x VEGF-A bispecific antibody) in patients with biliary tract cancer (BTC), prior to a potential BLA filing later this year. Tovecimig data from this study has also been selected for an oral presentation at the 2026 European Society for Medical Oncology (ESMO) Congress in October.

BOSTON, July 17, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that its abstract titled “A randomized trial of paclitaxel ± tovecimig in previously treated patients with advanced biliary tract cancer” has been accepted for an oral Proffered Paper presentation at the upcoming European Society for Medical Oncology (ESMO) Congress. The congress will take place October 23-27, 2026 in Madrid, Spain.

Compass Therapeutics is rated Buy, with risk/reward favoring upside after a sharp post-data selloff. CMPX's lead asset, tovecimig, showed strong PFS benefit in BTC, but OS crossover contamination clouds FDA approval prospects. The Q3 2026 FDA meeting is pivotal; approval could nearly double the stock, while rejection risks 50% dilution and multi-year delays.

Compass Therapeutics, Inc. (CMPX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

BOSTON, May 28, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that the Company will participate in the following investor events during the month of June.